

Supplementary Material

1. Supplementary Table S1. Bacterial strains and plasmids used in this study

Name	Relevant phenotype	Source /reference
Strains		
<i>B. subtilis</i> 168	Wide-type strain, <i>trpC2</i>	Lab stock (from China General Microbiological Culture Collection Center)
<i>BS168DR</i>	neomycin resistance	Lab stock & [12]
<i>S1</i>	Mutated from BS168DR, erythromycin and chloramphenicol resistance	Lab stock & [11]
<i>U1</i>	Mutated from S1, erythromycin and chloramphenicol resistance	This study
<i>U2</i>	Mutated from S1, erythromycin and chloramphenicol resistance	This study
<i>U3</i>	Mutated from S1, erythromycin and chloramphenicol resistance	This study
<i>U4</i>	Mutated from S1, erythromycin and chloramphenicol resistance	This study
<i>U5</i>	Mutated from S1, erythromycin and chloramphenicol resistance	This study
<i>U6</i>	Mutated from S1, erythromycin and chloramphenicol resistance	This study
<i>U7</i>	Mutated from S1, erythromycin and chloramphenicol resistance	This study

<i>U8</i>	Mutated from S1, erythromycin and chloramphenicol resistance	This study
<i>sinRm</i>	BS168DR, <i>sinR</i> *(G89R), neomycin resistance	This study
<i>icdm</i>	BS168DR, <i>icd</i> *(D28E), neomycin resistance	This study
<i>sinRm-CR</i>	BS168DR, <i>sinR</i> *(G89R)-CR, chloramphenicol resistance	This study
<i>icdm-CR</i>	BS168DR, <i>icd</i> *(D28E)-CR, chloramphenicol resistance	This study
<i>sim</i>	<i>icdm</i> , <i>sinR</i> *(G89R), neomycin resistance	This study

The resistance concentration used in this study were 60 µg/ml of neomycin, 20 µg/ml of erythromycin and 20 µg/ml of chloramphenicol respectively.

2. Supplemental Table S2. Primers used in this study

Name	Sequence (5'–3')
<i>sinRm</i> -UP1	CGTCGATCAAGGCTTAGGCT
<i>sinRm</i> -UP2	TCCAATTTTCGTTTGTTGAACTAATGGGTGCTTTAGTT GAAGACCATTCACTATCTAATTGACCATCGTATTCG
CR1	TCTTCAACTAAAGCACCCATTAGTTCAACA
<i>sinRm</i> -CR2	TCGATACCCTGGATGTCATCGCATCGCGAACCAATTT CTCCCATTCACCTATCTAATTGACCATCGTATTCGGTTT CATGTTTATTCATTCAGTTTTTCGTGCGGACT
<i>sinRm</i> -DN1	GAGAAATTGGTTCGCGATGCGAT
<i>sinRm</i> -DN2	GCTTTTGTGACGATCAGCAGC
<i>icdm</i> -UP1	CATCCCATGGCTGCTCTTCG

icdm-UP2	AATTTTCGTTTGTTGAACTAATGGGTGCTTTAGTTGA AGAGTTTGGTACGTTTAATACTCCGTTAGAGACTGTA A
icdm-CR2	CCGGTTCCTTCTCCTTCGATAAATGGGATAATCGGGT TGTTTGGTACGTTTAATACTCCGTTAGAGACTGTAAT TTTTTTATTCATTCAGTTTTTCGTGCGGACTG
icdm-DN1	AACCCGATTATCCCATTTATCGAAGG
icdm-DN2	AGGACATTCCGACAATTCGCC

3. Part of the fluorescence microscopy images




Figure S1 microscopy images at 4h




Figure S2 fluorescence microscopy images at 4h




Figure S3 microscopy images at 0h

References

11. Shouying, F.; Miaomiao, X.; Yining, Z.; Chuan, L.; Ran, T.; Dawei, Z. Establishment and Application of High-throughput Screening Method of Riboflavin Industrial Strain. *Biotechnol. Bull.* **2020**, *36*, 47.
12. Dawei, Z.; Yuan, S.; Bin, Y.; Chuan, L. Engineering Strain of *Bacillus subtilis* with High Vitamin B2 Production, Its Construction and Application. CN Patent 113025550B, 10 September 2021.